Unknown

Dataset Information

0

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.


ABSTRACT: Overexpression of the breast cancer oncogene HER2 correlates with poor survival. Current HER2-directed therapies confer limited clinical benefits and most patients experience progressive disease. Because refractory tumors remain strongly HER2+, vaccine approaches targeting HER2 have therapeutic potential, but wild type (wt) HER2 cannot safely be delivered in immunogenic viral vectors because it is a potent oncogene. We designed and tested several HER2 vaccines devoid of oncogenic activity to develop a safe vaccine for clinical use.We created recombinant adenoviral vectors expressing the extracellular domain of HER2 (Ad-HER2-ECD), ECD plus the transmembrane domain (Ad-HER2-ECD-TM), and full-length HER2 inactivated for kinase function (Ad-HER2-ki), and determined their immunogenicity and antitumor effect in wild type (WT) and HER2-tolerant mice. To assess their safety, we compared their effect on the cellular transcriptome, cell proliferation, anchorage-dependent growth, and transformation potential in vivo.Ad-HER2-ki was the most immunogenic vector in WT animals, retained immunogenicity in HER2-transgenic tolerant animals, and showed strong therapeutic efficacy in treatment models. Despite being highly expressed, HER2-ki protein was not phosphorylated and did not produce an oncogenic gene signature in primary human cells. Moreover, in contrast to HER2-wt, cells overexpressing HER2-ki were less proliferative, displayed less anchorage-independent growth, and were not transformed in vivo.Vaccination with mutationally inactivated, nononcogenic Ad-HER2-ki results in robust polyclonal immune responses to HER2 in tolerant models, which translates into strong and effective antitumor responses in vivo. Ad-HER2-ki is thus a safe and promising vaccine for evaluation in clinical trials.

SUBMITTER: Hartman ZC 

PROVIDER: S-EPMC2831125 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Hartman Zachary C ZC   Wei Junping J   Osada Takuya T   Glass Oliver O   Lei Gangjun G   Yang Xiao-Yi XY   Peplinski Sharon S   Kim Dong-Wan DW   Xia Wenle W   Spector Neil N   Marks Jeffrey J   Barry William W   Hobeika Amy A   Devi Gayathri G   Amalfitano Andrea A   Morse Michael A MA   Lyerly H Kim HK   Clay Timothy M TM  

Clinical cancer research : an official journal of the American Association for Cancer Research 20100223 5


<h4>Purpose</h4>Overexpression of the breast cancer oncogene HER2 correlates with poor survival. Current HER2-directed therapies confer limited clinical benefits and most patients experience progressive disease. Because refractory tumors remain strongly HER2+, vaccine approaches targeting HER2 have therapeutic potential, but wild type (wt) HER2 cannot safely be delivered in immunogenic viral vectors because it is a potent oncogene. We designed and tested several HER2 vaccines devoid of oncogenic  ...[more]

Similar Datasets

| S-EPMC6694677 | biostudies-literature
| S-EPMC3277145 | biostudies-literature
| S-EPMC5588880 | biostudies-literature
| S-EPMC7062719 | biostudies-literature
| S-EPMC3571712 | biostudies-literature
| S-EPMC4783217 | biostudies-literature
2008-11-22 | E-GEOD-13274 | biostudies-arrayexpress
| S-EPMC7501074 | biostudies-literature
2024-08-01 | GSE239649 | GEO
| S-EPMC10496496 | biostudies-literature